# Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

> **NCT02460367** · PHASE1 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 16 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Progression of Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** Tergenpumatucel-L
- **DRUG:** Indoximod

## Key facts

- **NCT ID:** NCT02460367
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2017-07-17
- **Final completion:** 2021-01-13
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Lack of enrollment and changing landscape of standard of care.
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02460367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02460367, "Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02460367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*